Combination for use in the treatment of lung cancer
US11304943B2 · kind B2 · utility
0Cited by
3References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 28, 2018 |
| Grant date | Apr 19, 2022 |
| Priority date | — |
| Expiry date | Mar 28, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention is based on the finding that co-administration of 6-β-naltrexol alongside vitamin D together with a chemotherapeutic agent, results in a further reduction in lung cancer cell growth. The combination of 6-β-naltrexol with vitamin D results in a greater decrease in the growth of cancer cells compared to the sum of the effects of each agent when administered in isolation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.